About: Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
Creator	Ahmed, S Chan, T Chen, Y Liu, Q Sami, A Xiang, J Xie, Y
Source	PMC
abstract	Approximately one third of patients with advanced human epidermal growth factor receptor 2 (HER-2)/neu-positive breast cancer respond to trastuzumab monotherapy, a humanized anti-HER-2/neu antibody. However, de novo and acquired antibody resistance is one of the major limitations of trastuzumab therapy warranting the search for other therapeutic strategies. One of the most remarkable features of adenovirus (AdV)-based vaccine is its ability to induce exceptionally high and sustained frequencies of transgene product-specific CD8(+) T-cell responses. In this study, we constructed two recombinant AdVs (AdV(OVA) and AdV(HER-2)) expressing ovalbumin (OVA) and HER-2/neu, and assessed AdV-induced antigen-specific cellular immune responses and preventive/therapeutic antitumor immunity. We demonstrate that AdV(OVA) stimulates efficient OVA-specific CD8(+) cytotoxic T lymphocyte (CTL) and natural killer responses, leading to preventive long-term immunity against OVA-expressing BL6-10ova melanoma in wild-type C56BL/6 mice. We further demonstrate that AdV(HER-2) stimulates HER-2/neu-specific CD8(+) CTL responses, leading to a significant reduction in breast carcinogenesis in transgenic FVBneuN mice (P<0.05), but has little therapeutic effect on pre-existing Tg1-1 tumor even at early stage (15 mm(3)). In contrast, the anti-HER-2/neu antibody therapy is capable of completely inhibiting Tg1-1 tumor growth at early stage, but fails to eradicate well-established Tg1-1 breast tumor (100 mm(3)). Interestingly, a combinatorial immunotherapy of anti-HER-2/neu antibody with AdV(HER-2) vaccine was capable of curing 4 of 10 studied mice bearing well-established Tg1-1 breast tumors and significantly delaying in death of the remaining six tumor-bearing mice (P<0.05). Taken together, our results suggest an adjuvant effect of AdV(HER-2) on anti-HER-2/neu antibody therapy for well-established breast tumor in transgenic FVBneuN mice, and this combinatorial immunotherapy of trastuzumab with AdV(HER-2) vaccine may be used as a new therapeutic strategy for treatment of advanced HER-2/neu-positive breast cancer.
has issue date	2011-05-13(xsd:dateTime)
bibo:doi	10.1038/cgt.2011.18
bibo:pmid	21566669
has license	no-cc
sha1sum (hex)	7e44fbe01010454789c97dcd18dd3ce6f10598fe
schema:url	https://doi.org/10.1038/cgt.2011.18
resource representing a document's title	Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
has PubMed Central identifier	PMC7091910
has PubMed identifier	21566669
schema:publication	Cancer Gene Ther
resource representing a document's body	covid:7e44fbe01010454789c97dcd18dd3ce6f10598fe#body_text
is schema:about of	named entity 'adjuvant' named entity 'preventive' named entity 'CTL' named entity 'expressing' named entity 'trastuzumab' named entity 'neu' named entity 'limitations' named entity 'stimulates' named entity 'immunity' named entity 'ovalbumin' named entity 'AdV' named entity 'transgenic' named entity 'tumor' named entity 'Adjuvant' named entity 'ABILITY TO' named entity 'EFFECT' named entity 'POSITIVE' named entity 'HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2' named entity 'THERAPY' named entity 'ASSESSED' named entity 'ANTIBODY' named entity 'FAILS' named entity 'APPROXIMATELY' named entity 'IMMUNE RESPONSES' named entity 'T-CELL' named entity 'IMMUNOTHERAPY' named entity 'USED' named entity 'BEARING' named entity 'MAY BE' named entity 'CD8' named entity 'ANTITUMOR' named entity 'CAPABLE' named entity 'BREAST' named entity 'PRE-EXISTING' named entity 'MAJOR' named entity 'SPECIFIC' named entity 'LONG-TERM' named entity 'CARCINOGENESIS' named entity 'FREQUENCIES' named entity 'STUDY' named entity 'SUGGEST' named entity 'MONOTHERAPY' named entity '28100' named entity 'TAKEN' named entity 'CELLULAR' named entity 'ADJUVANT' named entity 'RECOMBINANT' named entity 'ONE OF' named entity 'CONSTRUCTED' named entity 'BREAST TUMORS' named entity 'OVA' named entity 'FEATURES' named entity 'RESPOND TO' named entity 'TRASTUZUMAB' named entity 'TREATMENT' named entity 'ADENOVIRAL VECTOR' named entity 'TUMOR GROWTH' named entity 'COMPLETELY' named entity 'ADENOVIRUS' named entity 'RESULTS' named entity 'ADVANCED' named entity 'IMMUNITY' named entity 'ESTABLISHED' named entity 'TRANSGENIC' named entity 'ANTIBODY THERAPY' named entity 'STRATEGIES' named entity 'RESPONSES' named entity 'MELANOMA' named entity 'ANTIGEN' named entity 'OVALBUMIN' named entity 'PRODUCT' named entity 'SIGNIFICANT' named entity 'TUMOR' named entity 'BREAST TUMORS' named entity 'TRANSGENIC MICE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software